FDA Asks Stakeholders How It Can Improve Orange Book, Patent Listings

FDA on Friday (May 29) took several steps to improve and ramp up use of the agency’s Orange Book in a bid to provide more timely and accurate information about generic drugs and spur generic drug competition. The agency is asking stakeholders what type of patent information should be included in the Orange Book, how they use the publication and how the database can be improved . FDA is particularly interested in stakeholders’ views on how to list patents when...